EGFR and non-small cell lung carcinoma: Epidermal growth factor receptor (EGFR) inhibition is an established and effective treatment option for patients with non-small cell lung cancer (NSCLC) [1–4], colorectal cancer (CRC) [5, 6], and squamous cell carcinoma of the head and neck (SCCHN) [7].